Futures slip, bank earnings ahead, Powell to speak - what’s moving markets
Investing.com -- Eli Lilly’s international president Patrik Jonsson expressed uncertainty on Wednesday about the U.S. Food and Drug Administration’s new fast-track review process, saying the company may not use it for its experimental weight-loss pill orforglipron.
"There is very little knowledge about this national priority voucher today. I would not assume we will submit with a national priority voucher, because we do not fully understand what it contains," Jonsson said in an interview.
The comments suggest the pharmaceutical giant is taking a measured approach toward the FDA’s new review pathway rather than rushing to utilize it for its weight-loss medication pipeline.
Orforglipron remains one of Eli Lilly’s key experimental drugs in the increasingly competitive weight-loss treatment market.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.